# EDGAR Filing Document

**Accession Number:** 0001715925
**File Stem:** 0001193125-26-012376
**Filing Date:** 2026-1
**Character Count:** 6581
**Document Hash:** b8c488523db42224f4bf3dc8c61d6d4b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-012376.hdr.sgml**: 20260114

**ACCESSION NUMBER**: 0001193125-26-012376

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260114

**FILED AS OF DATE**: 20260114

**DATE AS OF CHANGE**: 20260114

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MindWalk Holdings Corp.
- **CENTRAL INDEX KEY:** 0001715925
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39530
- **FILM NUMBER:** 26531776

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 3204-4464 MARKHAM STREET
- **CITY:** VICTORIA
- **NON US STATE TERRITORY:** BRITISH COLUMBIA
- **PROVINCE COUNTRY:** A1
- **BUSINESS PHONE:** 6048060626

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 3204-4464 MARKHAM STREET
- **CITY:** VICTORIA
- **NON US STATE TERRITORY:** BRITISH COLUMBIA
- **PROVINCE COUNTRY:** A1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ImmunoPrecise Antibodies Ltd.
- **DATE OF NAME CHANGE:** 20170830

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**Form 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the month of **<u>January, 2026</u>**.

Commission File Number: **<u>001-39530</u>**

**<u>MindWalk Holdings Corp.</u>** 

**3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8**

(Address of principal executive office)

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit**<br>| &nbsp;&nbsp;&nbsp;**Description**<br>|
| &nbsp;&nbsp;99.1<br>| [<u>Press Release dated January 14, 2026</u>](hyft-ex99_1.htm) |

---

------

**<u>SIGNATURES</u>** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MINDWALK HOLDINGS CORP.** | **MINDWALK HOLDINGS CORP.** |
| Date: January 14, 2026 |  |  |
|  | By: | /s/ Jennifer Bath<br>|
|  | Name: | Jennifer Bath |
|  | Title: | President and Chief Executive Officer |

---

------

## Exhibit 99.1

99.1 **MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease** 

VICTORIA, British Columbia — MindWalk Holdings Corp. ("MindWalk" or the "Company") (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer's disease.

The work demonstrates MindWalk's ability to discriminate with structural precision between toxic protein conformations and their healthy counterparts, a long-standing challenge in neurodegenerative drug development. By defining the disease-driving structural state and anchoring it in bio-native wet-lab validation, the Company is resolving both the structural and functional logic of neurodegeneration and converting that understanding into selective, evidence-linked biological assets.

"This discovery validates our platform strategy," said Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk. "We are identifying disease-defining protein states and translating that insight into selective, validated assets with traceable biological evidence behind them."

Beyond the specific biology, the study provides external validation of MindWalk's platform capabilities in a client-driven setting and reinforces the Company's position as a trusted discovery partner for complex neurodegenerative programs.

The full scientific study, *<u>Rational Generation of Monoclonal Antibodies and Intrabodies Selective for Pathogenic TDP-43</u>*<u>, is available on bioRxiv (DOI: 10.1101/2025.06.10.658846)</u>.

**About MindWalk** 

**Investor Contact** 

Louie Toma, CPA, CFA <br>Managing Director, CoreIR <br><u>investors@mindwalkAI.com</u> 

Source: MindWalk Holdings Corp.

------

**Forward Looking Statement** <br>This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements regarding the significance of the discovery and validation described in this release, the Company's discovery capabilities and platform performance, the potential relevance or application of the monoclonal antibodies and intrabodies referenced, the ability to identify and characterize disease-driving protein states, the potential translation of preclinical findings into future research or development programs, and potential future collaboration, partnering, licensing, or commercialization opportunities.<br>

Forward-looking statements are based on management's current expectations and assumptions as of the date of this release and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the preliminary nature of scientific findings reported in a preprint that has not undergone peer review; the possibility that subsequent peer review, additional experiments, or further analysis may produce different or contrary results; scientific and technical challenges inherent in drug discovery and development; uncertainties regarding reproducibility, selectivity, safety, pharmacology, and manufacturability; uncertainties regarding the translation of preclinical findings into clinical outcomes; regulatory requirements and approval processes; the Company's reliance on third-party collaborators, clients, and partners; intellectual property risks and uncertainties; competitive developments; market and macroeconomic conditions; and the Company's ability to execute its strategy, secure resources, and manage growth.<br>

Except as required by law, MindWalk undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release.

------